Literature DB >> 11428630

A cutaneous full-thickness liquid sulfur mustard burn model in weanling swine: clinical pathology and urinary excretion of thiodiglycol.

J S Graham1, F M Reid, J R Smith, R R Stotts, E S Tucker, S M Shumaker, N A Niemuth, S J Janny.   

Abstract

Sulfur mustard (bis(2-chloroethyl)sulfide, HD) is a well-known blistering chemical warfare agent. We have developed a cutaneous full-thickness HD burn model in weanling pigs for efficacy testing of candidate treatment regimens. This report addresses clinical pathology findings and the urinary excretion profile of a major HD metabolite (thiodiglycol, TDG) in this model. Six female Yorkshire pigs were exposed to HD liquid on the ventral surface for 2 h, generating six 3-cm diameter full-thickness dermal lesions per pig. Blood samples were collected throughout a 7-day observation period for hematology and serum chemistry examinations. Urine was collected in metabolism cages. Routine urinalysis was performed and the urine analyzed for TDG using gas chromatography/mass spectrometry. Examination of clinical pathology parameters revealed subtle HD-related changes that are suggestive of a mild hemolytic episode. No other signs of clinically significant systemic toxicities were noted, including bone marrow suppression. Thiodiglycol was detected at the earliest time point tested (6-8 h post-exposure) at levels ranging from 0.66 to 4.98 microg ml(-1) with a mean of 2.14 microg ml(-1). Thiodiglycol concentrations were the highest for half of the animals at this earliest time point and at 24-48 h for the others. By the evening of day 3, the mean level had reached 50 ng ml(-1). Mean levels remained 10-40 ng ml(-1) for the remainder of the 7-day observation period, with the highest individual concentration noted during this period of 132 ng ml(-1). Our results are in general agreement with the TDG excretion profiles previously described for rodent models and humans. Urinary excretion of absorbed HD in our weanling pig wound healing model appears to follow the same pattern as is seen in other laboratory animals models. In general, urinary excretion of TDG appears to peak within the first 1-4 days following exposure, with detectable levels after 1 week. Relatively high urinary TDG levels may thus indicate agent exposure within the previous 96 h. Low levels significantly above natural background levels may indicate either exposure to low levels of agent or exposure that occurred more than 4 days prior to collection of the sample.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11428630     DOI: 10.1002/1099-1263(200012)20:1+<::aid-jat681>3.0.co;2-t

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  5 in total

Review 1.  Genetically engineered pig models for human diseases.

Authors:  Randall S Prather; Monique Lorson; Jason W Ross; Jeffrey J Whyte; Eric Walters
Journal:  Annu Rev Anim Biosci       Date:  2013-01-03       Impact factor: 8.923

2.  Germline transgenic pigs by Sleeping Beauty transposition in porcine zygotes and targeted integration in the pig genome.

Authors:  Wiebke Garrels; Lajos Mátés; Stephanie Holler; Anna Dalda; Ulrike Taylor; Björn Petersen; Heiner Niemann; Zsuzsanna Izsvák; Zoltán Ivics; Wilfried A Kues
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

3.  Phytocontact Dermatitis due to Mustard Seed Mimicking Burn Injury: Report of a Case.

Authors:  Hakan Yabanoglu; Sami Akbulut; Feza Karakayali
Journal:  Case Rep Med       Date:  2012-05-20

4.  Wound healing of cutaneous sulfur mustard injuries: strategies for the development of improved therapies.

Authors:  John S Graham; Robert P Chilcott; Paul Rice; Stephen M Milner; Charles G Hurst; Beverly I Maliner
Journal:  J Burns Wounds       Date:  2005-01-05

5.  Addition of epidermal growth factor improves the rate of sulfur mustard wound healing in an in vitro model.

Authors:  Claudia L Henemyre-Harris; Angela L Adkins; Augustine H Chuang; John S Graham
Journal:  Eplasty       Date:  2008-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.